A drug can be classified by the type of chemical of the energetic ingredient or by the nature in which it is used in treating a particular ailment. Each drug can classified into one or more drug classes. Proteasome is defined as a multi-unit enzyme complex found in the cytoplasm as well as the nucleus of all eukaryotic cells. It is responsible for degradation of damaged or unneeded intracellular proteins by proteolysis that is a chemical reaction that helps break peptide bonds. Proteins, which are to be destroyed, are easily recognized by proteasomes because of the existence of ubiquitin conjugated to the targeted protein. The ubiquitin-proteasome pathways play a crucial part in regulating concentration of the intracellular of specific proteins, thus maintaining homeostasis within the cells. Proteasome inhibitors help to avoid decomposition of these proteins, which can affect multiple signaling cascades within the cell. This form of disruptions of normal homeostasis mechanisms can lead to cell death. Inhibition of Proteasome also presents a very promising approach to cancer therapy by targeting the proteasome function in tumor cells specifically. These inhibitors can also be used alone or together with other cancer therapies in order to sensitize tumor cells and improve therapeutic benefits.
Below you will find a list of drugs that fall under the class of Proteasome Inhibitors
The functions of proteasome inhibitors include;
Proteasome can have some common side effects such as;
Proteasome inhibitor Bortezomib is known to interact contrary to high-risk myelodysplastic syndrome (MDS) cells in vitro and vivo. The result is that Bortezomib could induce growth arrest and also apoptosis in high-risk MDS cells in vitro and vivo. Also, it has a synergistic effect with AraC and DNR which are the two chemotherapeutic agents.
Similarly, Proteasome inhibitor bortezomib can be interacted with other apoptotic stimuli, including cytotoxic chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer. The result is that Bortezomib induces death of cells of androgen-dependent and independent prostate cancer lines.
Back to all Drug Classes